| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3358930 | International Journal of Antimicrobial Agents | 2013 | 6 Pages |
Abstract
Data regarding ceftaroline use for meticillin-resistant Staphylococcus aureus bacteraemia (MRSAB) are lacking. Here we review the outcomes of 31 patients with MRSAB treated with ceftaroline, including 9 patients with endocarditis. Clinical success was observed in 23 patients (74.2%). Adverse events associated with prolonged therapy were rare and included eosinophilic pneumonia, rash and diarrhoea. We conclude that ceftaroline can be used for MRSAB.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Hari M. Polenakovik, Craig M. Pleiman,